Epithelial-mesenchymal Transition Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET), are developmental programs that have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal. A549 VIM RFP Cell Line NEW HCT116 VIM RFP Cell Line NEW CRISPR/Cas9 gene-edited vimentin-RFP fusion protein Strong RFP signal upon vimentin induction Physiological E-cadherin expression in absence of EMT Lung or colon models currently available Increased invasive capacity following EMT TGFβ1-responsive (lung model) Sensitive to A83-01 and PP1 inhibition (lung model) miR-200 family inhibitor-responsive (colon model) Fluorescence-labeled EMT Reporter Validation of A549-Vim-RFP Upon EMT induction, the EMT reporter cell line undergoes morphological changes from epithelial to mesenchymal and demonstrates increased expression of Vim-RFP. Learn more about how ATCC created and validated these advanced EMT models from the flyer. EMT/MET Reporter Cells A549 Vim RFP Cell Line HCT116 Vim RFP Cell Line MDA-MB-231 Vim RFP Cell Line By utilizing the CRISPR/Cas9 gene editing, ATCC offers advanced EMT models of lung and colon carcinoma and an MET model of breast cancer. These cell lines serve as ideal in vitro models for metastasis studies and anti-cancer drug screening. Related Products A549 cells HCT116 cells MDA-MB-231 F12K Medium McCoy’s 5A Medium Fetal Bovine Serum ATCC can provide the basal culture medium and serum that you need to grow your EMT and MET cells. We also carry the parental A549, HCT116, and MDA-MB-231 cell lines.
Epithelial-mesenchymal Transition Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET), are developmental programs that have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop new reporter lines designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal. A549 VIM RFP Cell Line NEW HCT116 VIM RFP Cell Line NEW CRISPR/Cas9 gene-edited vimentin-RFP fusion protein Strong RFP signal upon vimentin induction Physiological E-cadherin expression in absence of EMT Lung or colon models currently available Increased invasive capacity following EMT TGFβ1-responsive (lung model) Sensitive to A83-01 and PP1 inhibition (lung model) miR-200 family inhibitor-responsive (colon model) Fluorescence-labeled EMT Reporter Validation of A549-Vim-RFP Upon EMT induction, the EMT reporter cell line undergoes morphological changes from epithelial to mesenchymal and demonstrates increased expression of Vim-RFP. Learn more about how ATCC created and validated these advanced EMT models from the flyer. EMT/MET Reporter Cells A549 Vim RFP Cell Line HCT116 Vim RFP Cell Line MDA-MB-231 Vim RFP Cell Line By utilizing the CRISPR/Cas9 gene editing, ATCC offers advanced EMT models of lung and colon carcinoma and an MET model of breast cancer. These cell lines serve as ideal in vitro models for metastasis studies and anti-cancer drug screening. Related Products A549 cells HCT116 cells MDA-MB-231 F12K Medium McCoy’s 5A Medium Fetal Bovine Serum ATCC can provide the basal culture medium and serum that you need to grow your EMT and MET cells. We also carry the parental A549, HCT116, and MDA-MB-231 cell lines.